Drug Trial Radar · NCT02697734
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Oct 3, 2016
Primary completion
Jun 19, 2019
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
Conditions
- Cushing's Disease
Interventions
osilodrostatDrug
In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
osilodrostat PlaceboDrug
Matching Placebo in the form of filmcoated tablets for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Randomized Participants With a Complete ResponseTime frame: at Week 12
Locations
36 sites in 14 countries. Site status is shown where the registry gives one.
University of Colorado Endocrinology Clinical Trials Unit
Aurora, Colorado
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Oregon Health and Science University SC LCI699C2301
Portland, Oregon
University of Pennsylvania Medical Center University of Pennsylvania
Philadelphia, Pennsylvania
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
San Pedro, San Jose, Costa Rica, Costa Rica
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Krakow, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Warsaw, Masovian Voivodeship, Poland
Novartis Investigative Site
Porto, Portugal
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Andalusia, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
A Coruña, Galicia, Spain
Novartis Investigative Site
Alzira, Valencia, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Lucerne, Switzerland
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Bangkok, THA, Thailand
Novartis Investigative Site
Istanbul, Turkey (Türkiye)
Novartis Investigative Site
Kocaeli, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.